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ABSTRACT 
 The ability to manipulate the interaction between small molecules and biological 
macromolecules towards the study of disease pathogenesis has become a very important 
part of research towards treatment options for various diseases. The work described here 
shows both the use of DNA oligonucleotides as carriers for a nicotine hapten small 
molecule, and the use of microsomes to study the stability of compounds derived to treat 
mitochondrial diseases.  
 Nicotine addiction is a worldwide epidemic because nicotine is one of the most 
widely used addictive substances. It is linked to early death, typically in the form of heart 
or lung disease. A new vaccine conjugate against nicotine held within a DNA tetrahedron 
delivery system has been studied. For this purpose, several strands of DNA, conjugated 
with a modified dTpT having three or six carbon atom alkynyl linkers, have been 
synthesized. These strands have later been conjugated to three separate hapten small 
molecules to analyze which conjugates formed would be optimal for further testing in 
vivo.  
 Mitochondrial diseases are hard to treat, given that there are so many different 
variations to treat. There is no one compound that can treat all mitochondrial and 
neurodegenerative diseases; however, improvements can be made to compounds 
currently under study to improve the conditions of those afflicted. A significant issue 
leading to compounds failing in clinical trials is insufficient metabolic stability. Many 
compounds have good biological activity, but once introduced to an animal, are not stable 
enough to have any effect. Here, several synthesized compounds have been evaluated for 
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metabolic stability, and several showed improved stability, while maintaining biological 
activity. 
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CHAPTER 1 
GENERAL INTRODUCTION 
 
1.1 Nicotine Addiction 
     Addiction is the compulsive need for a substance, and is considered to be a life-long 
mental disorder. It is further characterized by the use of a substance until the body and 
brain become physically dependent on continued use of the addictive substance.1 The 
physical dependence is related to dopamine release in the rewards and pleasure center of 
the brain after use of such a substance. After repeated use of the abused substance, the 
amount of dopamine released is decreased over time, which suggests that the body has 
developed a tolerance. Typically, once a foreign substance is detected in the body, the 
immune system is triggered to clear the body of the threat; however, this response is 
negated once tolerance is developed. In the case of developed tolerance, the body 
produces more binding sites to receptors in the brain, leading to larger doses of the 
abused substance being necessary to produce the same feeling given by dopamine 
release. The continuous cycle of developing a tolerance and requiring higher doses of the 
material to achieve the same effect is the cycle that causes addiction.2 An estimated 20% 
of regular drug users in the United States have a drug-dependency issue, as it is defined 
by the International Classification of Diseases and the American Psychiatric 
Association.1 Worldwide, substance abuse and drug dependency are leading causes of 
premature disease and death.1 Despite the number of people afflicted, treatment for 
addiction is limited primarily to behavioral support and counseling. For some abusive 
substances, pharmacotherapy options are available for use alongside counseling, but 
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many of these options have been associated with low levels of efficacy and the possibility 
of adverse reactions in patients.3-6  
     According to the World Health Organization (WHO), there are an estimated 1.3 
billion smokers currently in the world; this makes tobacco the most prevalent addictive 
substance in the world.7 Tobacco use is the leading cause of death by cancer, 
cardiovascular disease, and pulmonary disease and is believed to be directly responsible 
for approximately five million deaths per year.7,8 The WHO estimates that if current 
patterns continue, the number of deaths per year will increase to at least 10 million deaths 
a year by 2020.1 The addictive substance in tobacco is nicotine, which is absorbed 
directly via smoking or indirectly via inhalation, and once absorbed, begins to accumulate 
in the brain approximately seven seconds later (Figure 1.1).9 In the brain, nicotine binds 
to acetylcholine receptors, allowing for the immediate release of dopamine and 
adrenaline. The half-life of nicotine is two hours and it is readily metabolized by 
cytochrome P450 isoenzyme CYP2A6 into cotinine.1 The quick absorption and response 
time contribute to making nicotine the most widely abused substance worldwide. 
 
inhalation absorption
N
N
H
free nicotine
unconjugated
N
N
H
crosses blood-
brain barrier
 
 
Figure 1.1. Path of nicotine after absorption, without pre-treatment (adapted from ref. 1).  
 
 
     According to the Centers for Disease Control and Prevention (CDC), approximately 
75% of self-identified U.S. smokers want to quit, but only 5% are able to remain smoke-
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free after one year.1 The most effective treatment option and smoking cessation aid 
currently on the market is nicotine replacement therapy (NRT), which gradually 
decreases the nicotine dose introduced to the body with a low abuse liability, using gum, 
lozenges, or patches.10 Besides NRT, two other pharmaceutical options have been 
approved to treat nicotine dependence (Figure 1.2): atypical anti-depressant bupropion 
(Wellbutrin) and nicotine receptor partial antagonist varenicline (Chantix). These two 
pharmaceuticals are considered first-line therapies, which can be accompanied by 
second-line therapies such as anxiety medication, nicotine receptor antagonists, and 
others currently under investigation.11,12 However, these second-line therapies are the 
same pharmaceutical options linked to limited effectiveness. 
 
N
N
HN
varenicline Cl
H
N
O
bupropion  
Figure 1.2. Structures of pharmaceutical options for nicotine dependence treatment. 
 
1.2 Uses and Functions of Vaccines 
     According to the WHO, the most cost-effective treatment for controlling infectious 
diseases is vaccination.13 Effective vaccines work by blocking the effects of the target 
compound and then aiding in the elimination of said compound from the system. Though 
nicotine addiction is not an infectious disease, it affects a large part of the world 
population and is linked to causes of early fatality. Vaccines are effective at inducing two 
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kinds of immune responses. First the innate response is triggered, which recognizes a 
foreign compound is present and sequesters any compound perceived as threatening for 
removal from the system. Later, the adaptive response is triggered, which results in a 
more target compound-specific immune response. This more specific response allows for 
the selection, activation, and expansion of memory B and T cells.14 The memory B and T 
cells are then primed to take the same course of action to eliminate the target compound 
again if there is future exposure (Figure 1.2).14 Adjuvants, or immune-potentiators, are 
added to vaccines to elicit an enhanced activation and development of more antigen-
specific immune response. All approved vaccines licensed for use in the United States 
contain aluminum salts as the adjuvant.15,16 Another known adjuvant, the squalene-
containing micro-emulsion MF-59, has been approved for use in vaccines destined for 
locations outside the United States since 1997. Despite being proven safe for continued 
use in Europe for almost two decades, and proving to be a more effective adjuvant, the 
FDA has yet to approve the use of MF-59 in vaccines destined for use in the United 
States.17,18 MF-59 has been shown to enhance antibody and T-cell proliferative 
responses,18 however it cannot help produce potent TH1 T-cell responses.19 Recent 
evidence has shown that MF-59 promotes retention of unprocessed immune-complex 
bound antigen within the lymph node macrophage compartments, leading to the eventual 
deposit of this complex to activated follicular dendritic cells (FDCs), showing its ability 
to enhance the humoral immune response.20  
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Figure 1.3. Innate vs. adaptive immune response.14  
 
     The biggest obstacle for treatment of nicotine addiction is the speed with which 
nicotine is able to cross the blood-brain barrier (BBB) and bind to receptors in the brain. 
A vaccine against nicotine addiction would be a viable treatment option because vaccines 
are capable of producing nicotine-specific antibodies that would bind to nicotine, forming 
a complex too large to cross the BBB (Figure 1.3).21 Since nicotine is too small to initiate 
the necessary immune response, a structurally related nicotine hapten, linked to a 
biological macromolecule, is used to elicit the appropriate immune response. Once this 
linked product is inserted into a delivery system, the conjugated vaccine is formed.22 
Once the vaccine antigen conjugate is introduced to the immune system, the conjugate is 
presented by antigen-presenting cells (APCs) which recognize the conjugate using T-cell 
receptors (Figure 1.4), and then the APCs present the conjugate to the lymphocytes, 
causing release of cytokines and nicotine-specific antibodies (Figure 1.2). To be 
maximally effective, a nicotine vaccine conjugate must be able to induce production of a 
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large amount of antibodies that bind robustly to nicotine, stimulating the immunological 
memory. Booster shots are often used to maintain higher antibody levels in the blood so 
the immune system can be continuously stimulated, such that it can target and eliminate 
nicotine efficiently in the future.23 Several nicotine vaccine conjugates have been 
developed previously, though none have successfully completed phase III clinical trials.1 
Another vaccine candidate, synthesized by Selecta Biosciences, Inc., has entered phase I 
clinical trials. This vaccine conjugate is a synthetic nanoparticle nicotine vaccine, which 
may make it a more effective treatment option, as there will be no secondary responses to 
biological carriers.1 
 
inhalation absorption
N
N
H
nicotine bound
to antibodies
bound nicotine too
large to cross BBB
X
 
 
Figure 1.4. Path of nicotine after absorption, with vaccination (adapted from ref. 1). 
 
 
 
     Finding a conjugate effective enough for clinical trials is difficult and several 
parameters must be closely monitored. First, while the antibodies produced must be able 
to bind to nicotine quickly, the binding affinity must also be low enough that the complex 
can subsequently dissociate, enabling nicotine to be cleared from the system.24 Also, the 
length and position of linkers on the hapten conjugates are shown to play a role in 
selectivity. Longer linkers and linkers at the 6-position of nicotine have been shown to 
increase nicotine-specific antibody selectivity.25 The biggest issue is still the amount of 
time it takes for nicotine to reach the brain after absorption.21  
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Figure 1.5 Antigen presenting cells (APCs) bridge the gap between innate and adaptive 
immune responses leading to amplification of antigen-specific response.14 
 
 
1.3 Mitochondrial Respiratory Chain and Reactive Oxygen Species 
     Organisms depend on a continuous supply of energy in order to survive, in the form of 
adenosine triphosphate (ATP).26 Mitochondria are responsible for carrying out the 
necessary oxidative reactions required to synthesize the amount of ATP needed to keep 
the cellular functions intact, and most of these reactions occur within the mitochondrial 
respiratory chain.27, 28 As the mitochondria serve such an important role in the cell, it is 
not surprising that mitochondrial dysfunction is linked to several neurodegenerative 
diseases including Alzheimer’s disease (AD), MELAS and Friedreich’s ataxia 
(FRDA),29-32 and complete disruption of ATP synthesis and mitochondrial function leads 
to death, as shown by poisons such as cyanide.28 Approximately 85-90% of oxygen 
consumption by the cell is from the mitochondrial electron transport system, and oxidants 
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like reactive oxygen species (ROS) are produced as a byproduct of this process. In a 
typical healthy person, these oxidants are detoxified by antioxidant enzymes in the cell, 
but ROS generation can increase several-fold in the presence of certain drugs or toxins.33-
40 Increased ROS production, most likely caused by disruption of the electron transport 
chain, can overwhelm the detoxification enzymes and cause oxidative damage that 
impairs the ability of the mitochondria to make ATP. This damage contributes to issues 
such as aging and diseases.29-32 
     The electron transport chain has four main respiratory enzyme complexes arranged in 
a specific orientation in the mitochondrial inner membrane. Electrons pass through these 
four complexes and effect the translocation of protons into the inner mitochondrial 
compartment, which is then used by complex V, ATP synthase, to convert adenosine 
diphosphate (ADP) and phosphate (Pi) into ATP (Figure 1.5).28 The electrons that travel 
through the chain are generated originally from nicotinamide adenine dinucleotide 
(NADH), produced by oxidized nutrients. Complex I is known as NADH dehydrogenase 
and is over 900 kD in size. Complex I is L-shaped, having two major domains separated 
by a thin collar and participates in proton translocation as well as transferring electrons to 
CoQ.41-43 It has been found that the primary relevant site of ROS production for disease 
research is the flavin mononucleotide (FMN) group in Complex I.44 Complex II is known 
as succinate dehydrogenase and transfers electrons from succinate to CoQ. Complex II is 
not involved in the translocation of protons, and only participates in the electron transport 
chain by introducing electrons into the chain.45 Additionally, there is no transfer of 
electrons between Complex I and Complex II; however, both complexes donate electrons 
to Complex III through CoQ.  
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Figure 1.6. Mitochondrial respiratory chain.  
 
     The most well understood complex, Complex III, also known as cytochrome bc1, 
participates in the electron chain by delivering electrons from ubiquinol to cytochrome c. 
The redox reactions coupled with the generation of a proton gradient across the 
membrane in a process called the Q cycle. Complex III has several domains, only some 
of which have redox centers, and is postulated to be multifunctional.28 Complex IV, or 
cytochrome oxidase, acts as a proton pump, capable of pumping one proton per electron 
across the membrane, and is responsible for the majority of oxygen consumption in the 
respiratory chain.46 Cytochrome c, a substrate for Complex IV, donates electrons to the 
cytoplasmic side of the membrane, which are then transferred to the active site and used 
to reduce molecular oxygen to two water molecules, where the protons needed for the 
reaction are taken from the mitochondrial matrix side.28 Finally, Complex V, or 
mitochondrial ATP synthase, is a reversible enzyme capable of both synthesis and 
hydrolysis of ATP.47 
H+ H+ H+ H+ 
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     Reactive oxygen species (ROS) are produced as a byproduct of the redox reactions 
within the mitochondrial respiratory chain. The main harmful species are superoxide   
(O2-), hydrogen peroxide (H2O2), and the hydroxyl radical (⋅OH).48-51 Dismutation of 
superoxide by superoxide dismutase (SOD) can lead to formation of hydrogen peroxide, 
and an iron- or copper-catalyzed reaction with hydrogen peroxide can lead to the 
formation of the hydroxyl radical. All three species cause different patterns of disruption 
and enzyme inactivation within the mitochondrial respiratory chain.52-55 These 
differential effects are further accentuated after treatment with hydroxyl radical 
scavengers or antioxidant enzymes, like SOD. The superoxide dismutase enzyme controls 
the amount of superoxide accumulation, but has no effect on hydroxyl radicals, and vice 
versa after treatment with hydroxyl radical scavengers.55 Mitochondrial DNA encodes 
thirteen proteins which are all subunits of the mitochondrial respiratory chain.56 
Mutations in these proteins can cause a malfunctioning respiratory chain and excess 
production of ROS species, causing a variety of mitochondrial diseases. Even if there are 
no mutations, and the mitochondrial respiratory chain is functioning properly, the leakage 
of electrons from the respiratory chain contributes to normal aging.57-59    
 
1.4 Cytochrome P450 Enzymes and Metabolic Stability 
     Determination of the metabolic stability of a compound in vitro is arguably one of the 
most important assays to determine viability of a compound for clinical trials. A 
compound can suppress lipid peroxidation and ROS production very efficiently, but if the 
compound is not stable intracellularly, it will not be able to produce the desired effect in 
animals. In fact, low metabolic stability due to oxidation by the cytochrome P450 
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(CYP450) enzymes is a common issue in drug discovery.60 Cytochrome P450 enzymes 
are a superfamily of heme proteins that are arranged into families and subfamilies based 
on sequence homology.61-64 Cytochrome P450 enzymes are responsible for approximately 
80% of phase I metabolism of clinically used drugs, primarily isoenzymes from families 
1-3.65-68 Fifteen isoforms are directly involved in the metabolism of clinically used drugs, 
and 95% of this metabolism is completed by five different isoforms (Figure 1.7).69   The 
CYP1 family is involved in metabolizing antipsychotics and caffeine, the CYP2 family is 
responsible for the metabolism of over 50% of all frequently prescribed medication and 
nicotine, and the CYP3 family enzymes are able to metabolize several structurally 
diverse compounds, completed primarily by CYP3A4.66 Most cytochrome P450 enzymes 
are located in the smooth endoplasmic reticulum (ER), and a few are localized in the 
mitochondria.69 
 
 
 
Figure 1.7. Pie graph representing phase I metabolism responsibility per enzyme.69 
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     The metabolic assay is typically performed in liver microsomes or hepatocytes and 
results are analyzed using a mixture of chromatographic and mass spectrometry 
techniques. Due to the metabolic stability issue, several groups have tried to develop 
quick, efficient, high-throughput methods to complete metabolic stability assays in order 
to quickly evaluate large libraries of compounds for the most stable options.70-73 Many of 
these techniques require robotic systems70,71 or LC/MS/MS systems,72,73 which can be 
great for identifying specific metabolites for each compound tested. However, all of these 
techniques are expensive and beyond the realm of possibility for most research groups. 
Microsomes are artifacts of the cell made from the smooth ER that stick together after 
cells are lysed and centrifuged in the laboratory. Microsomes are able to retain the 
activities of key enzymes involved in drug metabolism that are typically found in the 
smooth ER such as cytochrome P450s, flavin monooxygenases, and 
glucuronosyltransferases.74 Incubation of test compounds with microsomes, later 
analyzed by HPLC for percent of compound remaining, may take longer, but is a more 
realistic option for many laboratories.  
     Aside from increased research on techniques for studying the stability of compounds, 
there has been increased research on what structural elements can be added to a potential 
drug compound and where on the molecule they can be added, to reduce the 
susceptibility to metabolic enzymes. Design of potential drug candidates starts with 
identifying which groups are required for good in vitro biological activity, and regions 
that have little to no impact on that desired activity. These are the areas where 
modifications should be made to improve stability without affecting biological activity.74 
Fluorine has been used to replace several different groups in currently marketed drugs to 
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impede racemization of compounds, or increase the biological half-life by impeding 
oxidative metabolism.75 Another simple modification to increase stability is replacing 
hydrogen with deuterium. Not all compounds will have improved stability with 
deuterium and it must be evaluated case by case, but several reports have showed 
increased tolerability, safety, and efficacy in drugs when certain hydrogen atoms are 
replaced with deuterium.76 Various other structural modifications are regularly explored 
to try to increase stability of tested compounds, including adding bulky groups like a t-
butyl to nitrogen, steric shielding, and constraining molecules in a certain shape to make 
it resistant to metabolism.77 
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CHAPTER 2 
SYNTHESIS AND PURIFICATION OF MODIFIED DNA STRUCTURES AS 
CONSTITUENTS OF THE BACKBONE OF A NICOTINE VACCINE CONJUGATE  
 
2.1 Introduction  
     In the last few years, the development of a nicotine vaccine to aid in smoking 
cessation has been explored. Several potential vaccine conjugates have been created, 
including Nic002 from Cytos Biotechnology and NicVax from GSK and Nabi 
Pharmaceuticals.1 Nic002, which is comprised of a recombinantly produced virus-like 
protein, performed well in phase I trials, but after phase II trials it was determined to be 
safe and well tolerated but not capable of producing high antibody titers. NicVAX, also 
known as 3-AmNic-rEPA, performed well in both phase I and II clinical trials, but in 
phase III clinical trials, there was no statistical difference between the NicVAX treatment 
group and the placebo group. A few other conjugates have been derived but none has 
made it past phase II clinical trials, as these conjugates have only shown a therapeutic 
effect in patients able to achieve higher levels of antibody titers in blood.1 The only 
remaining promising option in clinical trial stages is a synthetic nanoparticle nicotine 
vaccine made by Selecta Biosciences, Inc., Sel-068, which is currently in phase I clinical 
trials. The company believes that because the vaccine is fully synthetic, the only target is 
nicotine, and therefore no secondary responses to biological carriers or linker regions will 
occur.1  
     The goal of the study described here is to develop a more effective vaccine conjugate 
than the previously reported conjugates that failed in clinical trials. The conjugate will 
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differ from the previously reported conjugates, as the intention is to use DNA both as a 
scaffold and as a delivery system for the vaccine. The DNA serves as a biological 
molecule to which the nicotine hapten can be directly linked. The conjugate is then 
incorporated into a DNA tetrahedron for conjugate delivery. Previous studies of DNA 
tetrahedrons show that they can easily enter mammalian cells and remain mostly intact 
for 48 h after transfection.78 Such DNA tetrahedrons can also be designed specifically to 
change configuration in response to stimuli, releasing anything held inside.79-81 Another 
study has shown a strong and specific immune response to an antigen–adjuvant complex 
when attached to a DNA nanostructure scaffold (Figure 2.1).82  
 
 
Figure 2.1. Model of delivery for antigen–adjuvant complex encased within a DNA 
tetrahedron.82 
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     For the vaccine conjugate to be successful, optimization of the individual parts was 
addressed first. As nicotine itself is too small to create the necessary immune response, 
structural modifications, typically in the linker region, have been investigated. Several 
groups have explored this avenue exhaustively, changing the length, position, rigidity, 
and hydrophobicity parameters of each structurally modified nicotine hapten.83-88 To test 
the synthesized conjugates more efficiently and determine the best derivatives for further 
testing in animals, an in vitro screening assay comparing the binding affinities of each 
hapten to the nicotine-specific antibody was used. If there was poor binding, or too high 
an affinity, the respective hapten was eliminated from further testing. Moderate binders 
were tested further in vivo in mice after being bound to streptavidin (SA) as the carrier. 
The hapten–SA conjugates were evaluated for their IC50 values as well as antibody titer 
and the ratio of titer to IC50, defined as the quality index (QI), was used as a measure for 
identifying effective haptens for a vaccine.89 Streptavidin was chosen as the carrier 
because it is known to stimulate the immune system response and generally does not 
cause the mass production of anti-SA antibodies, an issue seen with other carriers.90 In 
this manner, haptens 1-3 (Figure 2.2) were chosen as candidates for further testing, and 
the hapten–SA conjugate is included in the final DNA tetrahedron structure.  
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Figure 2.2. The structure of haptens 1-3 in the azide form. 
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     As mentioned previously, DNA is intended for use as a scaffold for the hapten and as 
a delivery system for the whole vaccine conjugate. The DNA tetrahedron was designed to 
contain several CpG motifs known for improving immonogenicity,91 as well as an 
individual DNA strand, modified to contain a linker attached to the phosphate group of 
the penultimate base at the 5ʹ′-end of the DNA. As with the hapten, several structural 
modifications were tested to find optimal conditions. The linkers differed in length, 
ranging from one to six carbons between the phosphate group and reactive group at the 
end of the linker (Figure 2.3). This reactive group has to be able to react easily with the 
hapten conjugate so the two could be directly linked without affecting the DNA structure 
in any other way. Several groups were tested and an alkyne group was determined to be 
the most efficient. The alkyne could be used under click reaction conditions with the 
azide-functionalized hapten conjugates.92-94 Several different dTpT conjugates with 
varying linkers were synthesized. Not only did these conjugates differ in linker 
construction and length but also in conformation as both the R- and S-configurations of 
each analogue were synthesized.  In this study, the stereochemistry of the linkers is not 
necessarily important, as all DNA constructs in this study contain only one modified 
dTpT structure and serve as models for future constructs. In the future, DNA constructs 
will be synthesized with more than one modified dTpT analogue, and the hapten 
molecules conjugated to the linker should be facing out of the tetrahedron, rather than 
inside the tetrahedron. The stereochemistry of each modified dTpT used in these future 
syntheses will have to enable the formation of the structure such that the haptens are 
facing out, and will depend heavily on where in the DNA tetrahedron each modified 
dTpT is located.  
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Figure 2.3. Structures of linker-modified dTpTs tested in the course of this study. 
 
     Testing conjugates in vivo is both time-consuming and expensive. To determine which 
DNA–hapten conjugates would be worth evaluating in vivo, several shorter 
oligonucleotides, 11-nt in length were synthesized, and each was designed to contain a 
different linker-modified dTpT analogue. Several of these oligonucleotides could be 
synthesized in a short period of time and, after purification, each was subjected to a click 
reaction with each of the three haptens. These click reactions were run using a copper (I)-
catalyzed azide-alkyne [3 +2] cycloaddition (CuAAC), previously developed by Meldal 
et al.92 and Sharpless et al.,93 and more recently used by Caruthers et al.94 in an enzymatic 
assay of DNA oligonucleotides modified in the same manner (Scheme 2.1). These shorter 
oligonucleotides and click products allowed for a quicker evaluation of which linkers on 
the phosphate backbone and which hapten constructs might best suit this kind of vaccine 
construction. After syntheses of the various click conjugates, several conjugates were 
further evaluated in ELISA antibody binding assays. 
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Scheme 2.1. Representative scheme of the CuAAC click reaction (adapted from ref. 94). 
 
     After evaluation of the shorter oligonucleotide–hapten conjugates, a 41-nt DNA 
oligonucleotide was synthesized to contain a three-carbon alkynyl linker at the phosphate 
on the penultimate DNA base in the S-conformation (DMT–oligo 9S). This DNA 
oligonucleotide was then subjected to a click reaction with the azide-functionalized 
hapten 3 to form oligo 10S. This conjugate was purified and tested, as will be discussed 
in more detail later. The shorter oligonucleotides were characterized more easily via 
MALDI-TOF mass spectrometry. Typical DNA analysis via MALDI-TOF depends 
heavily on concentration and is much more involved than typical small molecule or 
protein analysis. Even with a very concentrated and desalted sample, due to the number 
of negative charges on the phosphate backbone, the DNA sample can readily absorb 
sodium ions; therefore, the desired peak is very broad. The hapten is quite small in 
comparison to the DNA oligonucleotide, and the resolution within the peak is only 
sufficient when analyzing the short oligonucleotide–hapten conjugates to determine the 
conjugate has been successfully formed and is not starting material. Unfortunately the 
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resolution decreases as the size of the DNA increases, and therefore the longer 
oligonucleotide–hapten conjugate could not be analyzed by MALDI-TOF successfully, as 
the peaks would show no definitive evidence of product formation versus only remaining 
starting material.  
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Figure 2.4. Possible DNA sequences with possible dTpT structures.  
 
 
2.2 Results 
     The aim of this study was to discover one or more DNA–hapten conjugates that could 
be incorporated into a DNA tetrahedron vaccine conjugate and elicit the production of 
anti-nicotine antibodies. Dr. Xiaowei Liu had already completed work on the DNA 
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tetrahedron structure so its composition was predetermined. Dr. Nour Eddine Fahmi 
completed the synthesis of the modified dTpT structures with the various linkers.  
     Previous work89 to evaluate the individually synthesized nicotine hapten structures for 
the IC50 values and anti-nicotine versus anti-hapten antibody titers revealed haptens 1-3 
as nicotine hapten analogues with favorable properties (Figure 2.2). Therefore, Dr. Arutla 
modified the structure of the haptens so that each was functionalized with an azide that 
could easily react with the alkyne on the linker attached to the phosphate group on the 
penultimate base at the 5ʹ′-end of the DNA to form the DNA–hapten conjugate. The 
azide-containing haptens were purified by reversed-phase HPLC and the retention times 
for each sample are represented in Table 2.1. All samples were purified on a Phenomenex 
Oligo-RP C18 analytical HPLC column (250 × 4.6 mm, 5 µ) using a gradient mobile 
phase of 90:10 5% CH3CN in 0.1 M triethylammonium acetate (TEAA)–MeOH to 40:60 
5% CH3CN in 0.1 M TEAA–MeOH over a period of 40 min at a flow rate of 1.0 
mL/min. The IC50 values for binding to the anti-nicotine antibody for each sample are 
also included in Table 2.1. For comparison, the IC50 of free nicotine to the nicotine 
antibody was determined to be 1,412 ± 250 nM.  
 
Table 2.1. Analytical data for hapten samples 1-3. 
 
Hapten Sample Retention Time (min) IC50 (nM) 
1 36.2 9.1 ± 5.7 
2 27 802 ± 75 
3 12.5 379 ± 56 
a90:10 to 40:60 5% CH3CN in 0.1 M TEAA buffer–MeOH over 40 min; flow rate 1.0 mL/min on a 
Phenomenex oligo-RP analytical column (250 × 4.6 mm, 5 µ). 
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     Shorter oligonucleotides, 11-nt in length, were synthesized containing each of the 
modified dTpT analogues. The linkers on the modified dTpT analogues include the three-
carbon alkynyl linker in both the R- and S-isomers (DMT–oligos 1R and 1S, 
respectively), as well as the six-carbon alkynyl linker in both the R- and S-isomers 
(DMT–oligos 2R and 2S, Figure 2.5). The modified dTpT structures were incorporated at 
the 5ʹ′-end of the 11-nt DNA sequences. Each sample was purified by reversed-phase 
HPLC under the same conditions as the hapten samples, and all four shorter 
oligonucleotide analogues had similar retention times (8.9 min to 9.5 min) and yields (78-
87%). The data for these oligonucleotides is presented in Table 2.2.  
 
Table 2.2. Analytical data for 11-nt DNA oligonucleotide starting materials. 
 
DNA sample Overall yield (%) Stepwise coupling efficiency (%) 
Retention time 
(min)a 
DMT–oligo 1R 83 98 9.5 
DMT–oligo 1S 87 99 9.3 
DMT–oligo 2R 78 97 9.1 
DMT–oligo 2S 87 99 8.9 
a90:10 to 40:60 5% CH3CN in 0.1 M TEAA buffer–MeOH over 40 min; flow rate 1.0 mL/min on a 
Phenomenex oligo-RP analytical column (250 × 4.6 mm, 5 µ). 
 
Each 11-nt DNA sample was then used in the click chemistry reaction with each 
of the hapten samples. To synthesize the DNA–hapten conjugates, we employed a copper 
(I)-catalyzed [3 + 2] cycloaddition (CuAAC click chemistry) previously used by the 
Caruthers laboratory94 for similar DNA modifications.  This reaction includes the use of 
30 equivalents of one of the hapten samples, five equivalents of CuSO4, ten equivalents 
   23 
of sodium ascorbate, and seven equivalents of tris(benzyltriazolylmethyl)amine (TBTA) 
for every one equivalent of the oligonucleotide sample used. Each DNA–hapten 
conjugate was again analyzed and purified by reversed-phase HPLC. The data for the 
conjugates formed using haptens 1 (Scheme 2.2) and 2 (Scheme 2.3) are summarized in 
Table 2.3 below. 
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Scheme 2.2. Scheme of DMT–oligo 3. 
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Scheme 2.3.  Scheme of DMT–oligo 5. 
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Table 2.3. HPLC retention time data for oligonucleotide–hapten 1 and 2 conjugates. 
DNA–hapten 1 conjugate Retention Time (min)a 
DMT–oligo 3R 31.4 
DMT–oligo 3S 30.8 
DMT–oligo 4R 30.5 
DMT–oligo 4S 31 
DNA–hapten 2 conjugate Retention Time (min)a 
DMT–oligo 5R 47.2 
DMT–oligo 5S 44 
DMT–oligo 6R 46 
DMT–oligo 6S 45.4 
a90:10 to 40:60 5% CH3CN in 0.1 M TEAA buffer–MeOH over 40 min; flow rate 1.0 mL/min on a 
Phenomenex oligo-RP analytical column (250 × 4.6 mm, 5 µ). 
 
 
     Although retention times are listed for DMT–oligos 3R, 3S, 4R, and 4S, the peaks 
observed during HPLC analysis were not very high, and the material collected at the 
retention time for each sample analyzed could not be analyzed by MALDI-TOF. Even if 
the samples could have been successfully analyzed by MALDI-TOF, the yields would 
likely have been too low to make any of these DNA–hapten 1 conjugates viable 
candidates for further investigation. It is possible the structure of hapten 1 inhibits 
formation of the presumed click product. When the DNA–hapten 2 conjugates were 
analyzed by HPLC the presumed product peaks were higher and much more convincing, 
suggesting a more viable option to move forward with. Finally, presented in Table 2.4 is 
the data from the conjugates synthesized using hapten 3 (Scheme 2.4).  As can be seen 
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from the table, these samples were successfully analyzed by HPLC and MALDI-TOF to 
show formation of the DNA–hapten 3 click conjugates. The click products were analyzed 
by MALDI-TOF using 3-hydropicolinic acid (3-HPA) in H2O as the matrix solution with 
the addition of ammonia-treated Dowex 50WX8 (H+) resin.  Combining the knowledge 
of the stronger IC50 value for hapten 3 over hapten 2 and the successful analysis of the 
DNA–hapten 3 conjugates by MALDI-TOF, allowed us to investigate the DNA–hapten 3 
conjugates further. The DMT–oligo samples 1R, 2R, 7R, and 8R were all deprotected 
with 80% AcOH in water and then Adejimi Adaralegbe analyzed these same samples in 
the ELISA antibody binding assay, comparing oligo 1R sample and oligo 7R click 
product with oligo 2R sample oligo 8R click product. The data is presented in Figure 2.6. 
Oligo 7R shows greater binding to the antibody, but oligo 8R shows a greater separation 
from oligo 2R starting material. 
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Scheme 2.4. Scheme of DMT–oligo 7. 
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Table 2.4. Analytical data for all oligonucleotide–hapten 3 conjugates. 
DNA sample Overall Yield (%) Retention Time (min) Mass Spec 
DMT–oligo 7R 57 16.4 4255.60 
DMT–oligo 7S 56 18.5 - 
DMT–oligo 8R 57 18.4 4344.86 
DMT–oligo 8S 56 20.4 - 
 
 
Figure 2.5. ELISA competition assay data determined by Adejimi Adaralegbe. 
 
     Once further analysis was completed on oligo 7R, the same modified dTpT analogue, 
S-conformation, was incorporated into the 41-nucleotide DNA sequence (DMT–oligo 9S, 
Scheme 2.5) and then purified by reversed-phase HPLC. All samples were purified on the 
Phenomenex Oligo-RP C18 analytical HPLC column (250 × 4.6 mm, 5 µ) using a 
gradient mobile phase of 90:10 5% CH3CN in 0.1 M TEAA–MeOH to 40:60 5% CH3CN 
Free Nic 
hapten 3 
oligo 1R 
oligo 7R 
oligo 2R 
oligo 8R 
 
IC50 (nM) 
132 
19.8 
32 
0.152 
------- 
0.605 
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in 0.1 M TEAA–MeOH over a period of 40 min at a flow rate of 1.0 mL/min. The 
retention time for DMT–oligo 9S starting material was 20.4 min.  
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Scheme 2.5 Synthesis of DMT–oligo 10S. 
 
     As shown in Scheme 2.5, to synthesize the DNA–hapten conjugate, we employed the 
same CuAAC click chemistry as used previously for the shorter oligonucleotide 
conjugates. The click chemistry product, DMT–oligo 10S, was analyzed by reversed-
phase HPLC and showed a retention time of 19.7 min. Unfortunately, this presumed 
product could not be successfully analyzed by MALDI-TOF. Therefore, to ensure that the 
peaks corresponding to the DNA starting material and the DNA–hapten conjugate were 
different, a co-injection analysis was completed by reversed-phase HPLC, which showed 
two separate peaks at 19.7 and 20.4 min (Table 2.5, Figure 2.6a). To verify further, the 
   28 
DNA starting material, oligo 9S, and the DNA–hapten conjugate, oligo 10S, were 
analyzed on a 10% denaturing PAGE gel (Figure 2.6b) by Dr. Xiaowei Liu and showed 
different mobilities.  
 
Table 2.5. Analytical data for oligo 9S starting material and oligo 10S click product. 
41-nt DNA sample Overall Yield (%) Retention Time (min) 
DMT–oligo 9S 30 20.4 
DMT–oligo 10S 87 19.7 
 
 
a)  b)  
Figure 2.6. a) HPLC trace of oligo 9S and oligo 10S as two separate peaks. b) 10% 
PAGE gel run by Dr. Xiaowei Liu; Lane 1 – oligo 10S, Lane 2 – oligo 9S, Lane 3 – 39-nt 
DNA sample.   
 
     The DNA–hapten conjugate, oligo 10S, and all starting materials, including oligo 9S 
starting material and hapten 3 were included in an ELISA antibody binding assay run by 
oligo 10S oligo 9S        1             2              3 
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Joseph Leal to determine the binding affinities for each structure to anti-nicotine 
antibodies. It was determined from this analysis that the DNA–hapten conjugate was 
stronger binder than the hapten conjugate alone (Figure 2.7), and the tetrahedron (TH) + 
oligo 10S was several-fold stronger than oligo 10S alone. The DNA–hapten conjugate, 
oligo 10S was desalted on a G-25 spin column and then successfully incorporated into the 
DNA tetrahedron (Figure 2.8), and further tested in mice. When compared to the mice 
being treated with the DNA tetrahedron alone with no oligo 10S, there was a statistically 
significant increase in the anti-nicotine antibody titer in mice that had been treated with 
the DNA-hapten conjugate containing DNA tetrahedron (Figure 2.9). 
 
 
Figure 2.7. ELISA competition assay completed by Joseph Leal. 
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Figure 2.8. Gel analysis by Dr. Xiaowei Liu showing incorporation of oligo 10S into the 
DNA tetrahedron. Lane 1 – 100 bp ladder; Lane 2 – DNA tetrahedron; Lane 3 – 
tetrahedron + 10S. 
 
 
 
Figure 2.9. Analysis of antibody titer in mice treated with the DNA tetrahedron 
containing oligo 10S–hapten 3 conjugate (left) vs. the DNA tetrahedron without oligo 
10S–hapten 3 conjugate (right). Analysis completed by Dr. Xiaowei Liu. 
 
   1         2         3 
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2.3 Discussion 
     Several past nicotine vaccine conjugate designs have failed,1 so the aim of this study 
was to optimize the design of a new vaccine conjugate to increase immunogenicity and 
specificity. Within the full scope of the overall study, in vitro and in vivo assays of 
synthesized hapten conjugates were completed, suggesting that haptens 1-3 were all 
strong binders with varying binding specificities for nicotine. Additionally, the DNA 
tetrahedron has undergone several sequence modifications, 3-D shape modifications, and 
environment modifications to enhance delivery of the vaccine conjugate to follicular 
dendritic cells (FDCs) to enhance the immune response against nicotine. The studies 
described herein pertain to the optimization of the DNA–hapten conjugates for use within 
the DNA tetrahedron structure.  
     The study began with the syntheses of 11-nucleotide DNA structures each containing 
one of the linker modifications. This process was a more efficient way to test the various 
linker-modified DNA–hapten conjugates that could be formed. All together, five linkers 
were incorporated successfully; however, one of the linker-modified structures was 
eliminated from further use because it was not designed to work with the CuAAC click 
reaction chemistry. The other four oligonucleotide constructs each included either the 
three-carbon alkynyl chain linker or the six-carbon alkynyl chain linker, in the R- or S-
configurations, known as DMT–oligos 1R, 1S, 2R, and 2S. All four shorter 
oligonucleotide structures had similar HPLC retention times, ranging from 8.9 to 9.5 min. 
Each of the four oligonucleotides was individually treated with each of the haptens 1-3 
and then purified by HPLC again. Haptens 1-3 are all strong binders to the nicotine 
antibody, however of the three, hapten 1 is the weakest binding analogue. The retention 
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times for hapten 1, hapten 2, and hapten 3 were 36.2 min, 27.0 min, and 12.5 min, 
respectively. There is a large difference between these retention times, despite similar 
structures. There is also a large difference between the corresponding click products, 
DMT–oligos 3-8R and S, however the patterns are not the same. The suspected reason for 
this is that the structure of hapten 1 may inhibit successful formation of the respective 
click products, and therefore the presumed product peaks for DNA–hapten 1 conjugates, 
DMT–oligos 4 and 5 may not correspond to the desired products. The material collected 
could not be analyzed by MALDI-TOF and therefore the retention times could be 
irrelevant to this study. Discussing the remaining two hapten conjugates, the analysis of 
both the hapten 2 and hapten 3 click products showed peaks that were much stronger than 
those of the hapten 1 click products. This evidence suggests that hapten 1 and click 
reaction conjugates DMT–oligos 3 and 4, R and S are not strong candidates for further 
evaluation. Additionally, an earlier study treating an oligonucleotide with a one-carbon 
alkynyl linker with hapten 1, failed to successfully form a click product, despite 
attempting several synthetic routes.  DMT–oligos 7R and 8R were successfully analyzed 
by MALDI-TOF with good resolution. The conjugates were deprotected after treatment 
with 80% AcOH and then analyzed in the ELISA antibody binding assay by Adejimi 
Adaralegbe, comparing oligos 7R and 8R to the respective starting materials, oligos 1R 
and 2R. While click sample oligo 7R showed better binding to the antibody, there was a 
higher degree of separation between click product oligo 8R and its starting material, oligo 
2R, which showed no competition at all in the assay.  
     Based on the positive outcomes in the in vitro assays performed on oligos 7 and 8, the 
modified dTpT structure from oligo 1 was incorporated into a longer, 41-nt DNA 
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oligonucleotide, known as DMT–oligo 9S. Hapten 3 was used for the CuAAC click 
reaction because it had shown consistently good results in all assays with and without 
DNA and showed the ability to induce higher antibody titers. The CuAAC crude reaction 
mixture was analyzed and purified by reversed-phase HPLC, with the DNA–hapten 
conjugate DMT–oligo 10S having a retention time of 19.7 min versus the starting 
material DMT–oligo 9S at 20.4 min and the hapten 3 at 12.5 min. Co-injecting the 
material collected at 19.7 min with DMT–oligo 9S starting material resulted in two 
separate peaks, indicating new material had been formed (Figure 2.6a). After collecting 
this product, and drying the sample under diminished pressure, it was analyzed by 
MALDI-TOF. However, after varying the matrix, the conditions, and the methods, there 
was very little success trying to characterize the desired product. As the mass of a DNA 
sample increases, the resolution decreases. Since the hapten being used had a molecular 
weight of only 399, it would be difficult to distinguish DMT–oligo 9S from DMT–oligo 
10S by MALDI-TOF, given the poor resolution. Therefore the DNA–hapten conjugate 
oligo 10S was analyzed on a 10% PAGE gel and showed a different mobility from the 
DNA starting material oligo 9S, showing more evidence that the desired product may 
have been formed. The sample could not be analyzed by MALDI, but the shorter 
oligonucleotide counterpart oligo 8, was successfully analyzed by MALDI, so it was 
reasoned that the desired product, oligo 10S was formed. As a result, this sample was 
further analyzed in ELISA antibody binding assays and oligo 10S showed a two- to three-
fold stronger binding to the nicotine antibody than hapten 3 alone. After further testing, 
oligo 10S was incorporated into the DNA tetrahedron. At first, incorporation yields were 
low, likely due to high salt content; however, after desalting the conjugate sample, 
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incorporation yields increased, so that the product could be tested in several mice 
simultaneously. Results so far, most recently analyzed two weeks after the second dose, 
showed a statistically significant increase of anti-nicotine antibody titer in mice treated 
with oligo 10S–hapten 3 conjugate containing DNA tetrahedron versus the DNA 
tetrahedron alone (Figure 2.9). The DNA tetrahedron alone does contain the hapten 3–SA 
conjugates but no oligo 10S–hapten 3 conjugate conjugate. Because these results were 
statistically significant but not overwhelmingly significant, the theory is that increasing 
the number of modified dTpT structures within the DNA starting material would increase 
the immunogenicity even more and show an even more significant result. Therefore, 
focus of the overall study has shifted to increasing the number of conjugation sites on the 
DNA rather than testing the best DNA–hapten conjugate formation.   
 
2.4 Experimental Procedures 
Materials 
     Materials for the DNA syntheses were purchased primarily from Azco Biotech, Inc. 
These included the dT-specific CPG columns and all necessary reagents for the synthesis 
aside from 3% dichloroacetic acid in dichloromethane, which was acquired from Glen 
Research Company. Automated syntheses were performed on an ABI 391 EP automated 
DNA synthesizer, each cycle of base addition taking between six and eight minutes. A 
fraction collector was set up to collect the cleaved DMT cation during each coupling step, 
which was later analyzed via UV/VIS on an Agilent Technologies Cary 60 UV/VIS 
spectrometer to determine stepwise coupling efficiencies. Samples purified via reversed-
phase HPLC were done so using a Phenomenex Oligo-RP C18 HPLC analytical column 
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(250 × 4.6 mm, 5 µ). The mobile phase was a gradient of 90:10 to 40:60 5% CH3CN in 
0.1 M triethylammonium acetate (TEAA)–MeOH. Solvents used for HPLC purification 
were HPLC grade, purchased from VWR, or buffer made using deionized water, acetic 
acid purchased from VWR, and triethylamine purchased from Alfa Aesar. 
Characterization of samples was completed using an Applied Biosystems MALDI-TOF 
DE-STR mass spectrometer, primarily using 3-hydropicolinic acid (3-HPA) in water as 
the matrix solution. Samples were further treated with the ammonium form of Dowex 
50WX8 (H+) resin.  
 
O NO
P
O
ODMTO N
O
NH
NH
O
O
O
O
HN O
OLIGO
OLIGO = CAG AGG CGT
O NO
P
O
ODMTO N
O
NH
NH
O
O
O
O
HN O
OLIGO
OLIGO = CAG AGG CGT
1
2
 
Overall procedure for synthesis and purification of DMT–oligos 1R,S and 2R,S.  
     Syntheses of 11-nt DNA conjugates were completed on an ABI 391 EP automated 
DNA synthesizer on a dT-CPG column. The desired sequence was programmed and the 
settings were adjusted to retain the DMT protecting group at the 5ʹ′-end of the sequence. 
The syntheses of the oligonucleotides followed the normal method using this synthesizer 
except the wait time after the coupling of the 5ʹ′-linker-modified dTpT conjugate of 
choice (denoted as ‘X’ in the sequence on the synthesizer) was increased from 15 s to 600 
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s. After each base-coupling step, the cleaved DMT ion was collected and further analyzed 
via UV/VIS for coupling efficiency and theoretical yield. When synthesis was complete, 
each synthesized oligonucleotide was cleaved from the synthesis column using 
concentrated NH4OH, which was incubated for 30 min in a 1-mL syringe set-up. This 
process was repeated four times and injected into a Teflon-lined vial after each 
incubation period. The collected material was degassed and lyophilized and then purified 
via reversed-phase HPLC on a Phenomenex Oligo-RP analytical HPLC column (250 × 
4.6 mm, 5 µ) using a gradient elution buffer of 90:10 to 40:60 5% CH3CN in 0.1 M 
TEAA–MeOH over a period of 40 min at a flow rate of 1.0 mL/min. The desired 
products were collected and dried using a DNA SpeedVac system to give 11-nt DNA 
oligonucleotide conjugates as colorless solids. See Table 2.2. 
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Overall method of purification for DMT–oligos 3R,S-8R,S. 
     The reaction was performed using one of the modified 11-nt DNA oligonucleotide 
starting materials, DMT–oligos 1R, 1S, 2R, or 2S, 30 equivalents of haptens 1, 2, or 3, 5 
equivalents of CuSO4, 10 equivalents of sodium ascorbate, and 7 equivalents of TBTA. 
The conditions are those described in a publication from the Caruthers laboratory.94 The 
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crude click reaction solution was dissolved in 1:1 5% CH3CN in 0.1 M TEAA–MeOH 
and then injected onto a Phenomenex Oligo-RP C18 analytical HPLC column (250 × 4.6 
mm, 5 µ) using a gradient elution buffer of 90:10 to 40:60 5% CH3CN in 0.1 M TEAA–
MeOH over a period of 40 min at a flow rate of 1.0 mL/min. Peaks corresponding to 
desired product were collected for each sample and then dried and redissolved in 50 µL 
of deionized H2O. This solution was then run through a G-25 spin column to desalt the 
sample and then the material was dried, and dissolved in another 50 µL of H2O. 
Concentration measurements were completed via UV/VIS on an Agilent Technologies 
Cary 60 UV/VIS spectrometer. The concentration was calculated from the absorbance 
using Beer’s Law, where the molar absorptivity was that of the DNA oligonucleotide plus 
that of the hapten. The product was then dried a final time using a DNA SpeedVac 
system, dissolved in 10 µL of H2O and mixed well with 30 µL of a saturated solution of 
3-hydropicolinic acid (3-HPA) in H2O. To this solution was added the ammonium form 
of Dowex 50WX8 resin (H+) and the mixture was vortexed for several minutes and then 
allowed to settle. One microliter of the solution without resin was used for analysis by 
MALDI-TOF to confirm that the peak corresponded to the desired product. See Table 2.1 
for hapten data, Table 2.3 and Table 2.4 for DNA–hapten conjugate data. 
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Synthesis and HPLC purification of oligo 10S. 
     The reaction was performed using 21.0 µg (0.17 µmol) of DMT–oligo 9S, 19.8 µg 
(4.96 µmol) of hapten 3, 2.06 µg  (0.83 µmol) of CuSO4, 3.37 µg (1.70 µmol) of sodium 
ascorbate, and 6.15 µg (1.16 µmol) of tris(benzyltriazolylmethyl)amine (TBTA). The 
conditions are the same as those reported in a publication from the Caruthers laboratory.94 
The crude click reaction solution was dissolved in 1:1 5% CH3CN in 0.1 M TEAA 
buffer–MeOH and then injected onto a Phenomenex Oligo-RP C18 analytical HPLC 
column (250 × 4.6 mm, 5 µ) using a gradient elution buffer of 90:10 to 40:60 5% CH3CN 
in 0.1 M TEAA buffer–MeOH over a period of 40 min at a flow rate of 1.0 mL/min. The 
trace showed the presence of three major peaks at 9.3, 12.3, and 19.7 min. The peak at 
9.3 min corresponded to a salt formed during the reaction, the peak at 12.3 min contained 
excess unreacted hapten, and the peak at 19.7 min contained the desired product. The 
desired peak was collected, dried, and then redissolved in 50 µL of deionized H2O. This 
solution was then passed through a G-25 spin column to desalt the sample and then the 
solution was dried, and the product was dissolved in another 50 µL of H2O. 
Concentration measurements were completed using UV/VIS on an Agilent Technologies 
Cary 60 UV/VIS spectrometer. The concentration was calculated from the absorbance 
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using Beer’s Law, where the molar absorptivity was that of the DNA oligonucleotide plus 
that of the hapten. The results indicated 17.3 µg (87%) of product (See Table 2.5). This 
material was then treated with 80% AcOH in water for 20 min to deprotect the 5ʹ′-DMT 
group and then the sample was diluted with EtOH and dried using a SpeedVac system. 
The dried sample was then washed again with four 1-mL portions of EtOH to remove all 
traces of AcOH, giving a final yield of 16.9 µg of deprotected click product, oligo 10S. 
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CHAPTER 3 
METABOLIC STABILITY OF COMPOUNDS SYNTHESIZED FOR 
MITOCHONDRIAL DISEASE TREATMENT 
 
3.1 Introduction 
     As noted previously, breakdown of the electron transport chain and associated 
oxidative stress is connected with the etiology of neurodegenerative and severe 
mitochondrial diseases. These include neurodegenerative diseases such as Alzheimer’s 
disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), Friedreich’s 
ataxia (FRDA), and Huntington’s disease (HD).95 Various mitochondrial diseases that 
serve as a model for neurodegeneration include Leber’s hereditary optic neuropathy 
(LHON), autosomal dominant optic atrophy (ADOA), Charcot-Marie-Tooth hereditary 
neuropathy type 2A (CMT2A), and myoclonic epilepsy with ragged red fibers (MERRF). 
Several other diseases are associated with mitochondrial respiratory chain dysfunction, 
including mitochondrial encephalopathy, lactic acidosis and stroke-like episodes 
(MELAS), Kearns-Sayre syndrome (KSS), and Leigh’s syndrome.96 Although the 
diseases differ in how mitochondrial dysfunction is related, and studies are still being 
carried out to determine whether mitochondrial dysfunction is part of the cause or effect 
of neurodegenerative diseases, what these diseases have in common is impaired 
respiratory chain activity or failure of mitochondrial function. The standard strategy for 
treatment of these diseases involves using analogues of coenzyme Q10 (CoQ10) and 
natural antioxidants to slow mitochondrial degradation.97 
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     Coenzyme Q10 is naturally occuring within the body and constitutes a vital part of the 
mitochondrial respiratory chain. Biosynthesis of CoQ10 occurs within all tissues and cells 
in the organism and the lipid is present in all membranes; higher amounts in an organelle 
typically reflect that it is used for several different functions.98 One of the primary roles 
of CoQ10 is as an antioxidant, the effectiveness of which comes from its ability to 
interfere with lipid peroxidation both in the initiation and propagation steps, by limiting 
production of lipid peroxy radicals (Figure 3.1).  It has been shown that in certain 
diseases where free radical production is part of the disease, such as AD and diabetes, 
increase of tissue CoQ10 is considered to be a protective mechanism. Non-natural CoQ10 
has been most commonly used for treatment of cardiomyopathy with improved heart 
function after administration.  In addition, some beneficial effects have been observed 
after administration of CoQ10 to patients with neurodegenerative diseases such as HD, 
PD, and ALS.99  
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Figure 3.1. Lipid peroxidation cycle and the actions of CoQ, and vitamin E.98 
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     One particular CoQ10 synthetic analogue, 2,3-dimethoxy-5-methyl-6-(10-
hydroxy)decyl-1,4-benzoquinone, more commonly known as idebenone (Figure 3.2), has 
been shown to accept electrons from mitochondrial Complex I, and to restore respiration 
in ubiquinone-deficient mitochondria.100 Although idebenone has been shown to be an 
efficient substrate for both Complex II and Complex III, it shows a significant inhibitory 
effect on Complex I.101 It has been suggested that the hydroxyl group of idebenone could 
undergo esterification in the blood or tissue, which could potentially negate the inhibitory 
interaction with Complex I.101, 102 Idebenone was originally designed as a neuroprotective 
agent, and has been the subject of a number of clinical trials, showing positive results in 
patients with LHON and Duchenne muscular dystrophy (DMD), but no statistical 
difference between treatment and placebo groups was observed when used to treat 
Friedreich’s ataxia.103-109 Another CoQ10 analogue, MitoQ, is similar to CoQ10 in 
structure (Figure 3.2), but contains the positively charged triphenylphosphonium ion. 
This addition to the structure allows MitoQ to be taken up rapidly across mitochondrial 
membranes without a carrier, and accumulate within the mitochondria. It has been 
studied extensively and proved to be a several hundred-fold more potent antioxidant than 
non-targeting antioxidants and was shown to protect against various forms of oxidative 
damage.110,111 Additionally, an interesting study on MitoQ showed that it had no positive 
effect in patients with PD, but the study was able to show that MitoQ can safely been 
administered orally for more than a year.112 
   44 
O
O
OH3C
OH3C
CH3
CH3
H
10
CoQ10
O
O
OH3C
OH3C
CH3
OH
idebenone
O
O
OH3C
OH3C
CH3
P
MitoQ  
Figure 3.2 CoQ analogues used in various clinical trials. 
  
     Another naturally occurring antioxidant, vitamin E (α-TOH or α-tocopherol), has 
been studied for its ability to decrease mitochondrial dysfunction. Vitamin E actually 
incorporates eight different structures, the α-, β-, γ-, and δ-tocopherols and α-, β-, γ-, and 
δ-tocotrienols, but α-tocopherol is the most active form.113 Additionally, in nature it is 
found in the R,R,R-α-tocopherol from, but when synthesized is generally made as the 
racemic mixture (Figure 3.3). While antioxidant activity amongst the eight stereoisomers 
is the same, biological activity is highest in analogues where the second stereocenter is in 
the R-conformation.113 Vitamin E, or more specifically α-tocopherol, is known as a 
chain-breaking antioxidant, meaning its antioxidant activity is expressed by preventing 
radical formation in the propagation stage of lipid peroxidation,114 unlike CoQ10 which 
was able to disrupt formation in both the initiation and propagation stages. Recently, 
dietary vitamin E has been shown to reduce some oxidative stress induced by 
doxorubicin without being able to repair mitochondrial dysfunction. Clinical use of 
doxorubicin in cancer chemotherapy has been shown to lead to development of 
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irreversible dilated cardiomyopathy.115 Studies have shown that this is likely caused 
because doxorubicin accepts electrons from Complex I, forming the unstable 
semiquinone radical of the drug. (Figure 3.4) 
 
O
HO
H H
 
Figure 3.3 Structure of natural R,R,R-α-tocopherol. 
 
     The unpaired electron then reacts with molecular oxygen to regenerate the drug at the 
expense of also producing superoxide.116 Rats were fed a normal diet supplemented with 
2 g/kg vitamin E, before receiving seven weekly injections of 2 mg/kg doxorubicin.117 
Unfortunately, after analysis there were high levels of α-tocopherol found in heart 
mitochondria, and there was an inhibition of oxidative injury in cardiac tissue, but the 
doxorubicin-induced cardiomyopathy was not improved upon at all with the vitamin E 
diet. This and other studies suggests that vitamin E, as is, may not be potent enough as an 
antioxidant to treat mitochondrial and neurodegenerative diseases.115,117-119 
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Figure 3.4. Structure of doxorubicin. 
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     Past work by the Hecht group involved optimization of structures based on α-TOH, 
CoQ10, and idebenone and the best qualities associated with analogues which led to the 
discovery of a desirable redox core, which then served as a basis to synthesize further 
analogues for study.97,120 The base analogues were capable of scavenging free radicals 
and preserving mitochondrial function when cells were under oxidative stress, and the 
analogues that performed best were subjected to structural modifications that could 
increase biological activity. The design of future analogues requires a structure resistant 
to metabolism by phase I enzymes, and which can augment production of ATP, suppress 
reactive oxygen species and lipid peroxidation, and perform well in several other 
categories.97  
     Additionally, based on past studies showing the efficacy of methylene blue in 
improving mitochondrial function in rats,121-123 some interesting structural optimizations 
of methylene blue and methylene violet  analogues were recently investigated.124 To test 
these analogues for biological efficacy, the analogues will be studied in a series of assays 
for suppression of ROS and lipid peroxidation, as well as their effect on mitochondrial 
membrane potential, and ability to protect cultured cells from oxidative stress induced by 
glutathione depletion. The analogues will also be tested for their ability to produce ATP 
and to interact with the electron transport chain, as well as for their stability in the 
presence of activated bovine liver microsomes.97 My study has involved evaluating 
metabolic stability of a number of structurally related analogues. The best analogues will 
then be used as a basis for further structural optimization and study. The primary goal is 
to be able to find an analogue that is stable within the liver microsomes, and also 
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performs well in suppressing ROS production and retains its ability to produce ATP in 
cells.  
 
3.2 Results 
     The aim of this work was to identify target compounds that could be used to treat 
various mitochondrial diseases. For a specific compound to be considered for further 
testing, it must perform well in several cellular-based assays, including the ability to 
induce ATP production, the ability to suppress lipid peroxidation and reactive oxygen 
species (ROS) production, and ability to maintain the membrane potential of the inner 
mitochondrial membrane. The metabolic stability assay determines whether or not a 
specific compound is stable enough to impart the desired effect on deficient cells before 
being metabolized. Previous work has been completed on the synthesis of various 
structural analogues of CoQ10 and α-tocopherol, leading to the discovery of a redox core 
with desirable qualities.97,120 Members of the Hecht laboratory have completed further 
modifications more recently, which were evaluated in the metabolic stability assay. 
Several earlier compounds that had previously undergone the metabolic stability assay 
with good results were used as control compounds. Previously prepared samples of 
microsomes were used to test the control compounds to ensure that the results were in 
line with previous reporting.  
     First, to be able to perform the metabolic stability assay, fresh microsomes had to be 
prepared from a fresh bovine liver. The liver was provided by JBS Tolleson, Inc. and was 
then used for microsomal preparation with the help of Dr. Omar Khdour. The 
microsomes were collected after ultracentrifugation, washed with buffer, and the 
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fractions combined. The combined fractions were then transferred to small sample 
containers in 0.5 mL aliquots, yielding about 50 samples for future use, which were 
frozen at –80 °C until needed. The first step of the metabolic stability assay was to 
determine the concentration of a sample aliquot using the BCA protein concentration 
assay, and then dilute the sample to a concentration of 1 mg/mL in 50 mM phosphate 
buffer, containing 5 mM MgCl2, at a pH of 7.4. For each sample being tested there were 
two centrifugation tubes filled with 0.5 mL of the diluted microsome solution, one for the 
activated microsomes, to be reacted with β-NADPH, and one for the deactivated 
microsomes to be immediately quenched, as a control.  
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Figure 3.5. Structures of compounds 1 through 4. 
 
     The previously tested compound 1, was compared in the metabolic stability assay with 
2, which contains an acetate group on the alcohol. Simultaneously, the newly synthesized 
compound 3 was compared to the previously tested compound 4 (Figure 3.5). Each 
sample was transferred to a separate sample vial for HPLC analysis, also containing 
fluorene as an internal standard at a concentration of 4 µM. The samples were analyzed 
by reversed-phase HPLC on a Zorbax SB-Phenyl Analytical HPLC column (150 × 4.6 
mm, 5 µ) using a gradient elution of 50:50 deionized H2O–MeOH to 100:0 deionized 
H2O–MeOH over a period of 14 min at a flow rate of 1.0 mL/min. All samples were 
analyzed in triplicate, and the average results are shown in Table 3.1.   
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Table 3.1. Stability data for compounds 1 through 4. 
 
Compound Recovery of test compound (%) 
1 56 ± 6 
2 84 ± 1 
3 65 ± 11 
4 69 ± 1 
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Figure 3.6. Structures of compounds 1, 3, and 5 through 14. 
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     In the same manner as described above, ten multifunctional radical quencher (MRQ) 
compounds were tested: 1, 3, and 5 through 12. Based on the data, shown in Table 3.2, an 
additional two compounds were added, 13 and 14 (Figure 3.6), which both contain an 
isopropyl group at the 4-position. The two samples differ in side chain length only; 
compound 13 contains a 16-carbon side chain, and compound 14 contains a 17-carbon 
side chain. The stability data for these additional compounds is also presented in Table 
3.2. 
 
Table 3.2. Stability data for compounds 1, 3, and 5 through 14. 
 
Compound Recovery of test compound (%) 
1 46  ±  8 
3 65 ± 12 
5 62 ± 10 
6 58 ± 11 
7 54 ± 11 
8 57  ±  8 
9 62  ±  6 
10 65 ± 10 
11 72  ±  9 
12 72  ±  8 
13 76 ±  7 
14 92  ±  6 
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Figure 3.7. Structures of compounds 3 and 15-21. 
 
 
     The next group of compounds tested in the metabolic stability assay contained various 
structural analogues of compound 3, synthesized by Dr. Arnaud Chevalier (Figure 3.7). 
Compound 3 has two major heteroatom-containing groups attached to the redox core. 
The other compounds tested in this assay have different variations of the placement of the 
same heteroatom groups. Analogue 15 has the same two groups in opposite positions, 
analogue 16 has cyclobutoxyl groups at both positions, and analogue 17 has azetidinyl 
groups at both positions.  These four analogues contain a 16-carbon side chain. Similarly, 
the 14-carbon side chain analogues for all four structural analogues were examined, 
known as compounds 18, 19, 20, and 21, respectively.  The stability results for these 
compounds are shown in Table 3.3. 
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Table 3.3. Stability data for structural isomers of compound 3. 
 
Compound Recovery of test compound (%) 
3 65 ± 7 
15 63 ± 9 
16 60 ± 7 
17 62 ± 3 
18 63 ± 2 
19 77 ± 4 
20 72 ± 4 
21 63 ± 5 
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Figure 3.8. Structures of compounds 3, 22-24. 
 
     Finally, Dr. Zhongjian Li synthesized three more compounds that differ from most of 
the previous structures in that a linker of varying lengths was added on the nitrogen, 
where there is typically a dimethylamine group or ring structure, and only a methyl group 
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where most of the previously shown structures have a 14- or 16-carbon side chain (Figure 
3.8). The linker length from the nitrogen group varies from four carbons to sixteen 
carbons in this assay, and all three compounds synthesized by Dr. Li were compared to 3 
for conformity. The results are summarized in Table 3.4. Although none of these 
compounds were found to have stability comparable to 3, the stability did seem to 
increase with an increase in the linker length.  
 
Table 3.4. Stability data for compounds synthesized by Dr. Zhongjian Li, compared to 
compound 3. 
 
Compound Recovery of test compound (%) 
3 65 ± 1 
22 52 ± 1 
23 44 ± 4 
24 48 ± 6 
 
3.3 Discussion 
     While there are well known compounds, such as idebenone, currently in clinical trials 
for use as a possible treatment for mitochondrial diseases, there are still many 
mitochondrial and neurodegenerative diseases where these compounds do not have any 
positive effect. Therefore, continuous structural optimization is completed on compounds 
like idebenone, and each of these new compounds synthesized has to undergo a series of 
assays to determine its biological activity and potential for future use in animal studies. 
The biggest issue is that many compounds perform well in cell-based assays, but fail 
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when analyzed in animal studies. Often this reflects a lack of metabolic stability. So one 
goal of structural modifications is to design compounds less prone to cellular metabolism 
while retaining their desired biological activities. 
     With that in mind, several multifunctional radical quenchers (MRQs) were 
synthesized based on the structure of compound 1. Compound 1 performed well in 
cellular assays, but in animal studies failed to show any positive effect. Compound 2 has 
the same structure as compound 1 but with an acetate group protecting the alcohol group 
(Figure 3.5). As can be seen from Figure 3.9, the acetate group confers increased 
metabolic stability. Additionally, compound 4 was an analogue that had previously been 
tested and published, and was shown to have a very high stability but limited biological 
activity. It was compared to compound 3, which had previously been synthesized but not 
studied in stability assays. Compound 3 showed a slightly lower, but comparable stability 
to compound 4.  
 
Figure 3.9. Metabolic stability data for compounds 1 through 4. 
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     With the stability issues of compound 1 in mind, several compounds were synthesized 
and divided into three different groups of modifications, using compound 1 as the parent 
compound (Figure 3.6). Compounds 6-9, 13 and 14 had an azetidine moiety rather than a 
dimethylated amine, and were structurally varied in the side chains. Compounds 3, 11, 
and 12 had a cyclobutoxy moiety in ring position 4, and the nitrogen-containing ring was 
varied in size from a four-membered ring to a six-membered ring. Finally, compounds 5 
and 10 were deuterium-containing analogues of the compound 1 structure.  The 
immediate goal of improving stability over that of compound 1 was achieved, as all other 
compounds tested in this assay were more metabolically stable (Figure 3.10). However, 
analyzing by group, the nitrogen-containing ring compounds had the highest stabilities 
overall, and the group with varied side chains at position 4 had the lowest stabilities 
overall. The deuterium containing analogues had metabolic stabilities that fell in between 
the other two groups (Figure 3.10). The reason the deuterium analogues were synthesized 
and included in this assay is because reports have showed that replacing hydrogen atoms 
selectively with deuterium can improve the stability of a compound while allowing the 
compound to keep its biological activity.76 When comparing the results of these 
compounds in the stability assay to the lipid peroxidation assay, a representative assay of 
the biological activity for each compound, the results generally oppose what was seen in 
the stability assay. Compounds 6-9 performed the best in terms of protection against lipid 
peroxidation, and compounds 3, 11, and 12, which were the most stable, gave much less 
protection against lipid peroxidation, although of the three compound 3 was the best. 
Compound 5 showed very good protection against lipid peroxidation, but compound 10 
did not show much protection, except at the highest concentration studied, 2.5 µM. The 
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real standout compound was 13. While compound 13 performed well in the stability 
assay, it also performed well in the biological activity assays, showing relatively good 
protection against lipid peroxidation and a reasonable ability to maintain the membrane 
potential within the mitochondria. Compound 14 was not studied further in biological 
assays. Its stability was even higher than compound 13, and it may well have similar 
activity in the biological assays to those of compound 13.  
 
 
Figure 3.10. Metabolic stability data for compounds 1, 3, and 5 through 14. 
 
 
     Compound 3 had one of the best metabolic stabilities but showed lower biological 
activity in assays performed in Friedreich’s ataxia cells, so further structural optimization 
was explored. By changing the positions of the azetidine and cyclobutoxyl groups, as 
well as varying the length of the long side chain between 14 and 16 carbons, the hope 
was to increase biological activity, while maintaining metabolic stability. Overall, the 
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stabilities for all eight compounds were comparable (Figure 3.11). The compounds with 
the highest stabilities were compounds 19 and 20, at 77% and 72%, respectively. This 
data suggests a level of dependence on side chain length, as these analogues both have a 
14-carbon side chain. This possible dependence on side chain length did not carry over to 
all of the analogues though. The average stabilities for the remaining six compounds were 
between 60 and 65%. The compounds had comparable levels of stability, but the lipid 
peroxidation assay results for these compounds showed much more variation. 
Compounds 3 and 18 (Figure 3.7), which have the same structure but with 16-carbon and 
14-carbon side chains respectively, both showed promising protection against lipid 
peroxidation. Compounds 15 and 19, the 16-carbon and 14-carbon analogues with the 
azetidine and cyclobutoxy moieties in opposite positions from compound 3, showed even 
better protection against lipid peroxidation than compounds 3 and 18.  Compounds 16 
and 20, the 16-carbon and 14-carbon analogues containing two cyclobutyl groups had 
almost no protection against lipid peroxidation. At higher concentrations of compound 
20, there was more protection against lipid peroxidation, but this pattern was not 
observed in compound 16. Compounds 17 and 21, which both contain the azetidine 
moiety at both positions, showed no protection against lipid peroxidation. Even at higher 
concentrations, the protection was minimal. 
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Figure 3.11. Metabolic stability for structural isomers of compound 3, 14-carbon and 16-
carbon side chain lengths. 
 
 
     Finally, the compounds synthesized by Dr. Zhongjian Li explored the position of the 
long chain, and what effect attaching it directly to the nitrogen may have. The structure 
also contains the cyclobutoxyl group at position 4 like compound 3 (Figure 3.8). With 
increasing chain length, the stability increased (Figure 3.12); however, the stability for all 
of the compounds was too low for the compounds to perform well in animal studies. 
Additionally, not all biological activity assays were completed on these compounds, but 
the overall data showed nothing remarkable about these analogues. 
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Figure 3.12. Metabolic stability for compounds synthesized by Dr. Zhongjian Li, 
compared to compound 3. 
 
 
3.4 Experimental 
Materials 
     The bovine liver microsomes used for the microsomal stability assay were prepared 
from a bovine liver provided by JBS Tolleson, Inc., with the help of Dr. Omar Khdour 
and then frozen at –80 °C. The Pierce BCA Protein Assay Kit from Thermo Fischer 
Scientific was used to determine the protein concentration of the samples as they were 
used. To determine stability, the prepared samples described below were analyzed by 
reversed-phase HPLC on a Zorbax SB-Phenyl reversed phase analytical (150 × 4.6 mm, 5 
µ) HPLC column using a mobile phase of MeOH–deionized H2O. A linear gradient was 
used, consisting of 50:50 MeOH–deionized H2O to 100:0 MeOH–deionized H2O over a 
period of 14 min at a flow rate of 1.0 mL/min. All buffers were prepared in deionized 
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water, and the β-NADPH solution and fluorene internal standard were both prepared 
fresh the day of the experiments. The β-NADPH and fluorene were both purchased from 
Sigma-Aldrich. The 1-propanol used in the quenching of the experiment and MeOH used 
for HPLC were both HPLC grade. 
 
Microsome Preparation from Bovine Liver 
     A fresh bovine liver was donated by JBS Tolleson, Inc. for this sample preparation. 
The liver was vacuum sealed and put on ice for transport. The liver tissue was cut into 
smaller pieces, which were then passed through the pre-cooled meat grinder and mixed 
well with three-fold isotonic sucrose buffer (0.25 M sucrose, 10 mM Tris-HCl, 0.5mM 
EDTA, pH 7.8). This ground mixture was then homogenized in a Waring blender for 25 
sec several times at high speed. The pH was periodically adjusted to 7.4 with 1 M Tris 
base during the homogenization step. The homogenate was centrifuged for 20 min at 
1200 g to remove cell debris. The supernatant suspension was further homogenized with 
a Potter-Elvehjem homogenizer in a tight-fitting glass tube. This suspension was then 
centrifuged four times at 10,000 g for 20 min. Each time the supernatant was collected 
and moved to a fresh sample tube, leaving behind the top floating layer of fat and the 
mitochondria layer stuck to the bottom. After the final centrifugation, the supernatant was 
then transferred to the centrifuge tubes for the Beckman-Coulter ultracentrifuge (XL-
100K-01, SW 55 Ti rotor) and centrifuged at 100,000 g for 1 h. The reddish supernatant 
was collected and the microsome fraction pellet was washed with 0.25 M sucrose buffer 
containing 10 mM Tris-HCl, pH 7.4 with 20% (v/v) glycerol, and then the pellets were 
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combined and transferred to sample containers in 0.5 mL aliquots and then stored at –80 
°C until such time as the samples were used in the microsomal stability assay. 
 
Microsomal Stability Assay 
     The concentration of the microsome aliquot was determined using the BCA protein 
concentration assay, and then the sample was further diluted to a protein concentration of 
1 mg/mL in 50 mM phosphate buffer, pH 7.4, containing 5 mM MgCl2. For each sample 
tested, the final incubation volume of suspended microsome solution was 0.5 mL, and the 
test compounds were added to the solution so that the final concentration in solution was 
25 µM. The mixture for each experiment was pre-warmed to 37 °C before addition of the 
β-NADPH solution until it reached 1 mM final concentration in the total reaction 
solution. The reaction was incubated at 37 °C for 30 min before being quenched by 1 mL 
1-propanol, vortexed for 2 min, and then centrifuged at 15,000 g for 15 min. The protein 
was precipitated and the supernatant was removed and concentrated under reduced 
pressure using a SpeedVac system. To each concentrated sample was added 130 µL of 
MeOH, and then the samples were centrifuged at 15,000 g for 5 min again. The 
supernatant of each sample was transferred to another sample container and 4 µM 
fluorene was added as an internal standard before analysis by reversed-phase HPLC. In 
addition to each activated microsome sample, for each compound being tested, a parallel 
experiment was run using inactivated microsomes, differing in preparation in that no β-
NADPH was added and the microsome sample was immediately quenched with 1-
propanol after addition of the compound being tested. Both samples for each compound 
were analyzed by HPLC on a Zorbax SB-Phenyl reversed-phase analytical (150 × 4.6 
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mm, 5 µ) HPLC column using a mobile phase of MeOH–deionized H2O. A linear 
gradient was used, consisting of 50:50 MeOH–deionized H2O to 100:0 MeOH–deionized 
H2O over a period of 14 min at a flow rate of 1.0 mL/min. Metabolic stability of the 
compounds was expressed as the percent of compound remaining, compared to the 
unreacted control. 
 
Compounds 1-4 
Refer to Table 3.1. 
 
Compounds 1, 3, and 5-14 
Refer to Table 3.2. 
Compounds 3, 15-21 
Refer to Table 3.3. 
 
Compounds 3, 22 through 24 
Refer to Table 3.4. 
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